Abstract:The levels of transcription factor Ets1 are high in resting B and T cells, but are downregulated by signaling through antigen receptors and Toll-like receptors (TLRs). Loss of Ets1 in mice leads to excessive immune cell activation and development of an autoimmune syndrome and reduced Ets1 expression has been observed in human PBMCs in the context of autoimmune diseases. In B cells, Ets1 serves to prevent premature activation and differentiation to antibody-secreting cells. Given these important roles for Ets1 in the immune response, stringent control of Ets1 gene expression levels is required for homeostasis. However, the genetic regulatory elements that control expression of the Ets1 gene remain relatively unknown. Here we identify a topologically-associating domain (TAD) in the chromatin of B cells that includes the mouse Ets1 gene locus and describe an interaction hub that extends over 100 kb upstream and into the gene body. Additionally, we compile epigenetic datasets to find several putative regulatory elements within the interaction hub by identifying regions of high DNA accessibility and enrichment of active enhancer histone marks. Using reporter constructs, we determine that DNA sequences within this interaction hub are sufficient to direct reporter gene expression in lymphoid tissues of transgenic mice. Further analysis indicates that the reporter construct drives faithful expression of the reporter gene in mouse B cells, but variegated expression in T cells, suggesting the existence of T cell regulatory elements outside this region. To investigate how the downregulation of Ets1 transcription is associated with alterations in the epigenetic landscape of stimulated B cells, we performed ATAC-seq in resting and BCR-stimulated primary B cells and identified four regions within and upstream of the Ets1 locus that undergo changes in chromatin accessibility that correlate to Ets1 gene expression. Interestingly, functional analysis of several putative Ets1 regulatory elements using luciferase constructs suggested a high level of functional redundancy. Taken together our studies reveal a complex network of regulatory elements and transcription factors that coordinate the B cell-specific expression of Ets1

Super-enhancers delineate disease-associated regulatory nodes in T cells

MLL4 Prepares the Enhancer Landscape for Foxp3 Induction Via Chromatin Looping

Foxp3 Enhancers Synergize to Maximize Regulatory T Cell Suppressive Capacity.

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Mapping the evolving landscape of super-enhancers during cell differentiation

Alternative Enhancer Usage and Targeted Polycomb Marking Hallmark Promoter Choice during T Cell Differentiation

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

CD8+ T Cells Utilize Highly Dynamic Enhancer Repertoires and Regulatory Circuitry in Response to Infections.

Super-enhancers: drivers of cells' identities and cells' debacles

Integrative analysis reveals genomic and epigenomic signatures of super-enhancers and its constituents

Super Enhancer-Mediated Upregulation Ofhjurppromotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Anatomy of a superenhancer

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma

Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes

Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes

A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies

Super‐Enhancer‐Driven IRF2BP2 is Activated by Master Transcription Factors and Sustains T‐ALL Cell Growth and Survival

Sequences within and upstream of the mouse Ets1 gene drive high level expression in B cells, but are not sufficient for consistent expression in T cells

Genome-wide Profiling in Colorectal Cancer Identifies PHF19 and TBC1D16 As Oncogenic Super Enhancers

Targeting super-enhancer activity for colorectal cancer therapy

The Hyper-Activation of Transcriptional Enhancers in Breast Cancer.